Prelude Therapeutics (PRLD) Stock Price, News & Analysis

Company Overview

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Key Stats

• Today's Range: $0.83 to $0.88
• 50-Day Range: $0.78 to $1.18
• 52-Week Range: $0.61 to $6.80
• Volume: 60,874 shs
• Average Volume: 121,844 shs
• Market Capitalization: $48.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

Prelude Therapeutics Stock Analysis - MarketRank™

Prelude Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 321st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Prelude Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Prelude Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Prelude Therapeutics are expected to remain at ($1.81) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Prelude Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Prelude Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Prelude Therapeutics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.14% of the float of Prelude Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Prelude Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Prelude Therapeutics has recently decreased by 4.56%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Prelude Therapeutics does not currently pay a dividend.

Dividend Growth

Prelude Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.14% of the float of Prelude Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Prelude Therapeutics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Prelude Therapeutics has recently decreased by 4.56%, indicating that investor sentiment is improving.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

63.90% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRLD Stock Analysis - Frequently Asked Questions

How have PRLD shares performed this year?

Prelude Therapeutics' stock was trading at $1.2750 at the beginning of 2025. Since then, PRLD stock has decreased by 32.7% and is now trading at $0.8575.

How were Prelude Therapeutics' earnings last quarter?

Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced its earnings results on Tuesday, May, 6th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.05.

When did Prelude Therapeutics IPO?

Prelude Therapeutics (PRLD) raised $149 million in an IPO on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities acted as the underwriters for the IPO.

Who are Prelude Therapeutics' major shareholders?

Top institutional investors of Prelude Therapeutics include Geode Capital Management LLC (0.39%) and Y Intercept Hong Kong Ltd (0.08%). Insiders that own company stock include Orbimed Advisors Llc, Krishna Vaddi, Andrew Combs and Laurent Chardonnet.
View institutional ownership trends.

How do I buy shares of Prelude Therapeutics?

Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Prelude Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Prelude Therapeutics investors own include Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Visa (V) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 8/08/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRLD
• CIK: 1678660
• Web: www.preludetx.com
• Phone: 302-467-1280
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Prelude Therapeutics: $4.50
• High Price Target: $5.00
• Low Price Target: $4.00
• Potential Upside/Downside: +424.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.17 million
• Net Margins: N/A
• Pretax Margin: -1,826.10%
• Return on Equity: -89.18%
• Return on Assets: -69.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.18
• Quick Ratio: 5.18

Sales & Book Value

• Annual Sales: $7 million
• Price / Sales: 6.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.39 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 56,460,000
• Free Float: 20,382,000
• Market Cap: $48.41 million
• Optionable: Optionable
• Beta: 1.22